Ocular Therapeutix plunges on missed endpoint in eye drug trial

Share of Ocular Therapeutix plunge after an eye drug candidate fails to meet an endpoint in a 2nd Phase III trial.

Ocular Therapeutix Inc.

News Well, Clinical Trials, Optical/Ophthalmic

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1Gkr7gc